Searchable abstracts of presentations at key conferences in endocrinology

ea0035s16.3 | Metformin: old dog, new tricks | ECE2014

Antitumoral effects of metformin on cancer stem cells: identification of novel molecular targets

Wurth Roberto , Gritti Marta , Angelini Marina , Barbieri Federica , Mazzanti Michele , Florio Tullio

Epidemiological and preclinical studies propose that metformin, a first-line drug for type- 2 diabetes, exerts direct antitumoral activity. Although several clinical trials are currently ongoing, the molecular mechanisms of this effect are unknown. The AMP-activated kinase-dependent pathway, and the down-stream effectors (e.g. mTOR) are considered the main effectors. Several studies reported the involvement of, in metformin metabolic activity. Nevertheless, contrasting evidenc...

ea0081oc7.1 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Splicing factor 3 subunit B1 (SF3B1) inhibition in PRL-secreting PitNETs and cross-talk with dopamine receptor type 2 (DRD2)

Di Muro Genesio , Mangili Federica , Barbieri Anna Maria , Esposito Emanuela , Treppiedi Donatella , Arlati Federico , Catalano Rosa , Marra Giusy , Nozza Emma , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Somatic mutations in splicing factor 3 subunit B1 (SF3B1) were found in about 20% of PRL-secreting PitNETs. SF3B1 is involved in pre-mRNA splicing and required for assembly of the U2 complex, which is critical for branch site recognition and the early stages of spliceosome assembly. Patients with mutant prolactinomas showed higher PRL levels and shorter progression-free survival compared to wild-type patients. Aims of the present study were: 1) to characterize the genetic prof...